Changes in plasma-free amino acid (PFAA) concentrations in the presence of
solid tumors have been widely described. Conversely, the PFAA profile in pa
tients with acute leukemias is less well defined. The aim of the present st
udy was to clarify whether the PFAA profile is altered in patients with acu
te myeloid leukemia (AML), whether the profile differs from the PFAA profil
e of solid tumors, and whether it may predict outcome of AML. Fasting PFAA
were measured in 40 untreated, normally nourished patients with PML (17 mal
es, 23 females), ages :22-78 y, with white blood cell (WBC) counts ranging
from 1.08 to 276.5 x 10(3)/cm(2), and in 24 healthy volunteers. Plasma conc
entrations (mu mol/L, mean +/- SE) of glutamic acid (GLU), free tryptophan
(FTRP), ornithine (ORN), and glycine (GLY) were significantly higher in AML
(GLU: 90.2 +/- 6.1 versus 37 +/- 8; FTRP: 7.0 +/- 0.6 versus 4.8 +/- 0.3,
P < 0.005; ORN: 108.7 +/- 5.8 versus 78 +/- 6, P < 0.001; GLY: 295.0 +/- 14
.8 versus 239 +/- 9, P < 0.01), whereas serine (SER), methionine (MET), and
taurine (TAU) were significantly lower in AML than in controls (SER: 109.0
+/- 5.8 versus 130 +/- 4, P < 0.03; MET: 25.5 +/- 1.3 versus 33 +/- 3, P <
0.03; TAU: 46.5 +/- 3.5 versus 81 +/- 2, P < 0.001), and tended to be even
lower in patients who had not responded to chemotherapy or had relapsed wi
thin 18 mo of enrollment. Such changes were unrelated to age, sex, and WBC
count. Changes in PFAA that occur in AML are only in part similar to those
observed in solid tumors. The reduction of TAU appears to be a typical feat
ure of AML and might be secondary to the deficiency of its precursors SER a
nd MET. Further studies are under way aimed at clarifying whether PFAA migh
t predict prognosis in AML, whether PFAA is normalized by remission inducti
on, and if its correction may be of any benefit for patients with hematolog
ic malignancies. Nutrition 1999;15:195-199. (C)Elsevier Science Inc. 1999.